Physician profile

Ivan Urits

Pain Medicine (Anesthesiology) · Wareham, MA

NPI 1346635422

$69,649.32

in general payments reported to CMS, 2019-2025

35 companies · $18K in 2025

The $18K reported for 2025 was more than what 97% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$14,962.50
Food and Beverage$10,858.17
Travel and Lodging$5,115.79

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Boston Scientific Corporation $29,984.92 2020-2025 Wavewriter Alpha Prime 16, Sidekick 2, Superion Indirect Decompression System
Vertex Pharmaceuticals Incorporated $16,700.63 2025
Mml US, INC. $3,102.99 2021-2023 Reactiv8
Nevro Corp. $2,986.47 2020-2024 Senza
Medtronic, INC. $2,748.50 2022-2025 Venaseal, Intellis Adaptivestim, Inceptiv
Painteq LLC $2,500.81 2021-2024 Painteq
Saluda Medical Americas, INC. $1,679.50 2023-2024 Evoke Scs, Evoke
Abbott Laboratories $1,436.09 2020-2024 Proclaim, Octrode
Nalu Medical, INC. $1,280.81 2021-2025 Nalu Neurostimulation System
Spinal Simplicity, LLC $1,071.31 2024 Ha Minuteman G3-R, Liberty Si
Pacira Pharmaceuticals Incorporated $814.73 2022
Abbvie INC. $732.77 2022-2025 Ubrelvy, Qulipta
Stryker Corporation $688.10 2025 Spinejack, Mild Device Kit
Stimwave Technologies Incorporated $522.81 2020-2022
Vertos Medical, INC. $451.47 2020-2024 Mild Device Kit
Show all 35 companies
CompanyGeneral paymentsYearsTop products
Spr Therapeutics, INC $389.47 2020-2023 Sprint Pns System
Globus Medical, INC. $357.70 2025 Senza, Vyrsa V1
Biotronik Nro, INC. $324.22 2024-2025 Prospera
Valinor Pharma, LLC $303.75 2023-2025 Movantik
Curonix LLC $254.96 2023-2024 Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A
Biohaven Pharmaceuticals, INC. $226.10 2020-2021
Pfizer INC. $211.56 2020-2025
Lilly USA, LLC $172.54 2023-2025 Emgality, Reyvow
Biohaven Pharmaceutical Holding Company Ltd. $154.45 2022
Medtronic USA, INC. $144.16 2020
Cala Health, INC. $116.87 2022
Relievant Medsystems, INC. $99.60 2021
Biodelivery Sciences International, INC. $34.81 2021
Spinefrontier, INC. $32.31 2020
Eisai INC. $30.87 2025
Livanova USA, INC. $27.08 2024 Vns Therapy Sentiva Model 1000 Generator
Acadia Pharmaceuticals INC $24.03 2024 Daybue
Alexion Pharmaceuticals, INC. $21.13 2023 Ultomiris
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $13.30 2024 Relistor
Grt US Holding, INC. $8.50 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Ivan Urits

$69,649.32

in general payments reported 2019-2025

Years
2020-2025
Top company
Boston Scientific Corporation
Context
The $18K reported for 2025 was more than what 97% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).

https://glasscript.com/doctor/7704929/ivan-urits

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.